Alliance Pharma (GB:APH) has released an update.
Alliance Pharma has announced a delay in publishing its preliminary results for the year ended 2023, now expected in early May. The audit by Deloitte LLP requires more time, although the company confirms the accuracy of its previous trading update. Alliance continues to focus on organic growth, innovation, and selective acquisitions to expand its consumer healthcare brand reach globally.
For further insights into GB:APH stock, check out TipRanks’ Stock Analysis page.
